Diffusion tensor imaging can accurately assess renal changes in kidney disease patients with diabetes

In diabetic patients with early-stage chronic kidney disease (CKD), diffusion tensor imaging (DTI) can accurately assess early renal function changes, reported authors of a new Clinical Radiology study.

“…The present data suggest that DTI is a useful non-invasive technique for detecting subtle events during early diabetic renal damage, and for monitoring the effects of various interventions,” wrote X.J. Ye, with Shandong University in China, and colleagues.

The researchers performed DTI on 36 diabetes mellitus patients and 26 healthy controls between September 2016 and September 2017. Apparent diffusion coefficient (ADC) and fractional anisotropy (FA) were calculated from the renal cortex and medulla. Those measures were correlated with estimated glomerular filtration rate (eGFR) and urinary biomarkers—two widely used markers to identify early kidney damage, the authors noted.

Results showed a “significant” decrease in FA values in the renal cortex and medulla in early-stage CKD diabetes patients, according to Ye XJ et al. Those FA values also correlated with eGFR and some with UA1MCR and UTRFCR. The authors noted they only saw an increasing ADC value trend in the renal cortex and medulla of diabetic patients.

“These results suggest the presence of physiological dysfunction and pathological changes in the very early stage of diabetes, prior to eGFR decline or macro-albuminuria detection,” the authors wrote.

“Overall, these data suggest that, at the very early stages of renal impairment, a progressive decline in FA values occurs with gradual development of renal impairment,” they concluded.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.